Nurse Resources

As a primary point of contact for patients, the role of the nurse is pivotal to the continuum of care. While this can be true for any patient, it is especially true for hematology patients undergoing immunotherapy.

In supporting the patient or caregiver, the nurse will assist countless times throughout the course of the patient journey. This assistance can take many forms, including discussions on disease-management options, consent, treatment, identification and monitoring of adverse events, and coordination of the multidisciplinary team. Because treatments are often administered in regional specialized centers, isolation and anxiety can add to an already uncertain future caused by a poor prognosis: The nurse becomes the patient's compass and ensures a comprehensive approach to a complex situation.

By giving more nurses greater access to the specialized immunotherapy knowledge and skills needed to actively role manage their patients, and by creating an online environment that nurtures a transparent exchange of ideas, information, and intelligence, we are helping more nurses to make a difference. We believe medical education should be for everyone. 


CAR T-Cell Therapy: High Response Rates, High Toxicity Rates

Andrew D. Zelenetz, MD, PhD, medical oncologist and medical director of quality informatics at Memorial Sloan Kettering Cancer Center recently discussed CAR T-cell therapy for this patient population at the NCCN 2020 Virtual Congress on Hematologic Malignancies.

Visit website
nurse 2

Cancer immunotherapy update

Because cancer treatment (surgery, radiation, and chemotherapy) frequently fails, research­ers began asking why patients’ immune systems don’t respond to cancer cells like they do to bacteria and viruses.

Visit website
ImmunotherapyWebsite Nurses Patients 56

A Beginners Guide to Immunotherapy

In this half-day course, Dr Vickers describes the logic behind many immunotherapies for cancer such as checkpoint inhibitors and more.

Visit website
ImmunotherapyWebsite Nurses Patients 57

Immunotherapy Side Effects: What Nurses Should Look Out For

As immunotherapy evolves it is crucial that nurses know the dangerous AEs to look out for.

Visit website
ImmunotherapyWebsite Nurses Patients 71

Apheresis in adults and pediatrics

Access this patient care session on Apheresis in adults and pediatrics, by Daphna Hutt, from the 2nd European CAR T Meeting (2020).

Visit website

EHA Guidance Document: The Process of CAR T-Cell Therapy in Europe

This document has been created to provide practical guidance for centers and national authorities in Europe that are interested in introducing chimeric antigen receptor (CAR)-T cell therapy.

Visit website
ImmunotherapyWebsite Nurses Patients 72

CAR T-cell therapy - guidelines for nurses

Orla Stewart, RN, of King's College Hospital NHS Foundation Trust, London, UK, discusses CAR T-cell therapy, including the patient journey, the adverse events faced and how to treat. Ms. Stewart also talks about the EBMT Nurses' Group aimed at better supporting nurses in transplantation.

Visit website
ImmunotherapyWebsite Nurses Patients 73

Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients

Immune checkpoint inhibitor (ICI) therapy is a fast-developing field within the spectrum of cancer care. ICIs are associated with distinctive immune-related adverse events (irAEs), reflecting their unique mechanisms of action.

Visit website

Immunotherapy Side Effects: What Nurses Should Look Out For

Oncology nurses are usually on the forefront of handling adverse events (AEs) associated with cancer treatments. Now, as immunotherapy continues to evolve in the lung cancer treatment landscape and other malignancies, it is crucial that nurses know the dangerous AEs to look out for.

Visit website
ImmunotherapyWebsite Nurses Patients 74

Managing CAR T-Cell Therapy in Patients With Hematologic Malignancies

Stephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.

Visit website